Upgrade to SI Premium - Free Trial

ResMed (RMD) Reiterated at Hold by Stifel Amid Concerns Over FY28 Revenue Growth Decelerating

October 2, 2026 8:01 AM
Stifel analyst Jonathan Block reiterated a Hold rating and $235.00 price target on ResMed (NYSE: RMD).The analyst commented, "Our survey ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments